New hope for hemophilia: Long-Acting drug shows promise in chinese trial

NCT ID NCT05082116

Completed Disease control Sponsor: Novo Nordisk A/S Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a medicine called turoctocog alfa pegol (N8-GP) in 36 Chinese men with severe hemophilia A, a bleeding disorder. The drug helps blood clot and was given as an injection to prevent or stop bleeding episodes. The trial lasted about 7-8 months and measured how many bleeds occurred per year and how well the drug controlled bleeding.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HAEMOPHILIA A are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hemophilia A

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HAEMOPHILIA A

Contacts and locations

Locations

Beijing Children's Hospital, Capital Medical University

Beijing, Beijing Municipality, 100045, China
Fujian Medical University Union Hospital-Hematology

Fuzhou, Fujian, 350001, China
Institute of Hematology and Blood Diseases Hospital, Tianjin-Hematology

Tianjin, Tianjin Municipality, 300020, China
Institute of hematology and Blood Diseases Hospital, Tianjin

Tianjin, Tianjin Municipality, 300020, China
Jinan Central Hospital

Jinan, Shandong, 250013, China
Nanfang Hospital, Southern Medical University-Haematology

Guangzhou, Guangdong, 510515, China
Qinghai Provincial People's Hospital

Xining, Qinghai, 810007, China
The Affiliated Hospital of Guizhou Medical University-Hematology

Guiyang, Guizhou, 550004, China
The First Affiliated Hospital of Soochow University

Suzhou, Jiangsu, 215006, China
The Second Affiliated Hospital of Kunming Medical University

Kunming, Yunnan, 650101, China
Xiangya Hospital Central-South University

Changsha, Hunan, 410008, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.